Skip to content
value.today

Evommune, Inc.

EVMN
$282 Mmarket cap on Oct 30, 2026
1M
-29.1%
Compare
World rank
#15,028
Revenue
$13 M
For year ending December-2025
Net income
$-69 M
-529.8% margin
SEC filing
Employees
48
As of December 31, 2025
SEC filing

Evommune, Inc. in brief

Evommune, Inc. is a listed company in the Biotechnology industry, based in Palo Alto, California, USA. Its market value was $282 M on 30 October 2026, which makes it the 15,028th largest listed company in the world and the 2,931st largest in the USA on this site. In the year to December 2025 it had sales of $13 M and a net loss of $69 M. It employs about 48 people and Luis C. Pena is its chief executive. Its shares trade under the symbol EVMN (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Evommune, Inc.

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis. Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

From the company's annual report filed with the US SEC: read the report

Evommune, Inc. timeline

2 events, 2025
  1. 2025
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on NYSE
    Final prospectus filed with the SEC on 6 November 2025; shares registered for exchange trading on 4 November 2025.

Events of Evommune, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$144 M$287 M$431 M$575 M

World rank over time

▼ down 3,055 places since 2026
2026-08-01: #12016#12,01620262026-09-23: #13661#13,66120262026-10-30: #15071#15,0712026

Rank in USA: #2,498 (Aug 2026) · #2,665 (Sep 2026) · #2,935 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
21.7×
Price / book
1.4×
Free cash flow yield
-27.2%
Net margin
-529.8%
Operating margin
-623.6%
Return on equity
-33.5%
Liabilities / assets
8.6%
Revenue growth
+85.7%
R&D / revenue
569.5%
Revenue per employee
$271 K
Profit per employee
$-1.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue $7M, net income $-67M$7MFY24Fiscal year ending Dec 2025: revenue $13M, net income $-69M$13MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$13M+85.7%$-81M$-69M-529.8%
Dec 2024$7M—$-70M$-67M-954.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-76M$0M$-77M$-11.22—
Dec 2024$-58M$0M$-58M$-45.29—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-16M—Sep ’24Three months to Mar 2025: revenue $3M, net income $-15M$3MMar ’25Three months to Jun 2025: revenue —, net income $-14M—Jun ’25Three months to Sep 2025: revenue $10M, net income $-12M$10MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-28M—Dec ’25Three months to Mar 2026: revenue —, net income $-22M—Mar ’26Three months to Jun 2026: revenue —, net income $-32M—Jun ’26Three months to Sep 2026: revenue —, net income $-31M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-31M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Evommune, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$13 M
Operating income
$-81 M
Net income
$-69 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$225 M
Total liabilities
$19 M
Total equity
$206 M

As of December-2025

Top 100 institutional investors in Evommune, Inc.#

As of Sep 30, 2026
104 institutions held 33.5 M shares (about 81.0% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Evommune, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1EQT Fund Management S.a r.l.5,288,3130 (0.00%)12.79%$44 MNov 12, 2026
2Ra Capital Management, L.P.3,494,6380 (0.00%)8.45%$29 MNov 16, 2026
3Point72 Asset Management, L.P.2,434,080+999,031 (+69.62%)5.89%$20 MNov 16, 2026
4Pivotal bioVenture Partners Investment Advisor LLC1,926,9430 (0.00%)4.66%$16 MNov 13, 2026
5Nan Fung Group Holdings Ltd1,441,0320 (0.00%)3.48%$12 MNov 13, 2026
6Defilade Capital Management, L.P.1,430,573+637,428 (+80.37%)3.46%$12 MNov 16, 2026
7Vestal Point Capital, LP1,250,000+250,000 (+25.00%)3.02%$10 MNov 16, 2026
8Baker Bros. Advisors LP1,234,794+387,404 (+45.72%)2.99%$10 MNov 16, 2026
9Kynam Capital Management, LP1,200,000New2.90%$10 MNov 16, 2026
10BlackRock, Inc.1,154,070+267,532 (+30.18%)2.79%$10 MNov 13, 2026
11Vanguard Capital Management LLC1,004,473+122,578 (+13.90%)2.43%$8 MNov 13, 2026
12Price T Rowe Associates Inc /MD/851,866-1,089,073 (-56.11%)2.06%$7 MNov 16, 2026
13Millennium Management LLC847,296New2.05%$7 MNov 16, 2026
14American Century Companies Inc762,340+7,322 (+0.97%)1.84%$6 MNov 12, 2026
15Qube Research & Technologies Ltd684,713+654,598 (+2173.66%)1.66%$6 MNov 13, 2026
16Silverarc Capital Management, LLC594,027New1.44%$5 MNov 12, 2026
17Barclays PLC526,560+347,830 (+194.61%)1.27%$4 MNov 6, 2026
18Geode Capital Management, LLC467,271+165,512 (+54.85%)1.13%$4 MNov 6, 2026
19Velan Capital Investment Management LP456,255+5,000 (+1.11%)1.10%$4 MNov 16, 2026
20Sphera Funds Management LTD.390,632+368,000 (+1626.02%)0.94%$3 MNov 16, 2026
21Citadel Advisors LLC379,729+369,005 (+3440.93%)0.92%$3 MNov 16, 2026
22Jane Street Group, LLC330,031+97,591 (+41.99%)0.80%$3 MNov 12, 2026
23Great Point Partners LLC325,0000 (0.00%)0.79%$3 MNov 16, 2026
24Goldman Sachs Group Inc301,400+108,405 (+56.17%)0.73%$2 MNov 16, 2026
25Trexquant Investment LP284,954New0.69%$2 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Evommune, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26State Street Corp267,910-25,606 (-8.72%)0.65%$2 MNov 12, 2026
27Two Sigma Investments, LP259,835+234,309 (+917.92%)0.63%$2 MNov 16, 2026
28Cantor Fitzgerald, L. P.257,505+153,913 (+148.58%)0.62%$2 MNov 16, 2026
29BNP Paribas Financial Markets243,511+110,161 (+82.61%)0.59%$2 MNov 12, 2026
30RTW Investments, LP208,071-1,294,164 (-86.15%)0.50%$2 MNov 16, 2026
31SummitTX Capital, L.P.201,714New0.49%$2 MNov 16, 2026
32FMR LLC168,774+168,610 (+102810.98%)0.41%$1 MNov 10, 2026
33XTX Topco Ltd166,671+105,977 (+174.61%)0.40%$1 MNov 16, 2026
34Orbimed Advisors LLC161,0000 (0.00%)0.39%$1 MNov 16, 2026
35Y-Intercept (Hong Kong) Ltd158,813+130,415 (+459.24%)0.38%$1 MOct 16, 2026
36Nuveen, LLC158,160+137,261 (+656.78%)0.38%$1 MNov 10, 2026
37Vanguard Fiduciary Trust Co152,823+64,624 (+73.27%)0.37%$1 MNov 13, 2026
38Charles Schwab Investment Management Inc150,907+17,835 (+13.40%)0.36%$1 MNov 16, 2026
39Northern Trust Corp136,970+35,566 (+35.07%)0.33%$1 MNov 16, 2026
40Vanguard Portfolio Management LLC136,265+16,338 (+13.62%)0.33%$1 MNov 13, 2026
41HRT Financial LP127,306New0.31%$1 MNov 13, 2026
42NEXTBio Capital Management LP119,0630 (0.00%)0.29%$1 MNov 13, 2026
43D. E. Shaw & Co., Inc.99,944New0.24%$1 MNov 16, 2026
44Andera Partners97,362-1,294,628 (-93.01%)0.24%$1 MOct 16, 2026
45Morgan Stanley94,573-195,601 (-67.41%)0.23%$1 MNov 13, 2026
46Jump Financial, LLC84,023+53,823 (+178.22%)0.20%$1 MNov 13, 2026
47ADAR1 Capital Management, LLC82,350-21,685 (-20.84%)0.20%$1 MNov 16, 2026
48Squarepoint Ops LLC79,696+31,994 (+67.07%)0.19%$1 MNov 9, 2026
49Walleye Capital LLC78,967New0.19%$1 MNov 13, 2026
50Marshall Wace, LLP76,811New0.19%$1 MNov 13, 2026
51Seven Grand Managers, LLC50,000-40,568 (-44.79%)0.12%$0 MNov 16, 2026
52Algert Global LLC48,814New0.12%$0 MNov 17, 2026
53Alps Advisors Inc47,737+11,179 (+30.58%)0.12%$0 MNov 3, 2026
54Atom Investors LP42,125New0.10%$0 MNov 16, 2026
55TD Asset Management Inc40,394-20,268 (-33.41%)0.10%$0 MNov 13, 2026
56Jpmorgan Chase & Co40,065-1,513,067 (-97.42%)0.10%$0 MNov 12, 2026
57Silverback Asset Management LLC40,000New0.10%$0 MNov 16, 2026
58Balyasny Asset Management L.P.35,868-421,147 (-92.15%)0.09%$0 MNov 16, 2026
59Bank Of America Corp /de/35,085+24,217 (+222.83%)0.08%$0 MNov 16, 2026
60Bank of New York Mellon Corp28,911+3,360 (+13.15%)0.07%$0 MNov 5, 2026
61Manufacturers Life Insurance Company, The27,289-11,619 (-29.86%)0.07%$0 MNov 13, 2026
62Vestcor Inc24,570New0.06%$0 MNov 12, 2026
63Schonfeld Strategic Advisors LLC21,450New0.05%$0 MNov 16, 2026
64UBS Group AG20,970-392,583 (-94.93%)0.05%$0 MNov 10, 2026
65US Bancorp \de\19,000New0.05%$0 MNov 5, 2026
66Axq Capital, LP16,864New0.04%$0 MNov 12, 2026
67Virtus Investment Advisers, LLC16,003-497 (-3.01%)0.04%$0 MNov 12, 2026
68Alliancebernstein L.P.15,7600 (0.00%)0.04%$0 MNov 16, 2026
69Canada Pension Plan Investment Board15,200New0.04%$0 MNov 16, 2026
70Rhumbline Advisers14,805+310 (+2.14%)0.04%$0 MNov 10, 2026
71Susquehanna International Group, LLP13,920+736 (+5.58%)0.03%$0 MNov 16, 2026
72Deutsche Bank AG\11,085-1,526 (-12.10%)0.03%$0 MNov 6, 2026
73Vanguard Global Advisers, LLC8,679+4,919 (+130.82%)0.02%$0 MNov 13, 2026
74MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.7,388+1,550 (+26.55%)0.02%$0 MNov 16, 2026
75Wells Fargo & Company/mn4,709-7,357 (-60.97%)0.01%$0 MNov 16, 2026
76New York State Common Retirement Fund4,3000 (0.00%)0.01%$0 MNov 17, 2026
77Russell Investments Group, Ltd.4,152-43 (-1.03%)0.01%$0 MNov 6, 2026
78Natixis3,365-1,679 (-33.29%)0.01%$0 MNov 6, 2026
79Police & Firemen's Retirement System of New Jersey3,0060 (0.00%)0.01%$0 MNov 9, 2026
80Citigroup Inc1,926-4,326 (-69.19%)0.00%$0 MNov 4, 2026
81Group One Trading LLC1,900New0.00%$0 MNov 10, 2026
82Caitong International Asset Management Co., Ltd1,561+1,272 (+440.14%)0.00%$0 MOct 29, 2026
83Tower Research Capital LLC (TRC)1,484-1,388 (-48.33%)0.00%$0 MNov 16, 2026
84Legal & General Group Plc1,231-7,290 (-85.55%)0.00%$0 MNov 16, 2026
85Royal Bank Of Canada919+227 (+32.80%)0.00%$0 MNov 16, 2026
86Ameritas Investment Partners, Inc.8550 (0.00%)0.00%$0 MNov 13, 2026
87State of Wyoming554-284 (-33.89%)0.00%$0 MOct 28, 2026
88Global Retirement Partners, LLC552New0.00%$0 MNov 10, 2026
89Sterling Capital Management LLC416+371 (+824.44%)0.00%$0 MOct 22, 2026
90PNC Financial Services Group, Inc.351+259 (+281.52%)0.00%$0 MNov 6, 2026
91Nisa Investment Advisors, LLC300+271 (+934.48%)0.00%$0 MOct 20, 2026
92Farther Finance Advisors, LLC265New0.00%$0 MOct 8, 2026
93GAMMA Investing LLC231+207 (+862.50%)0.00%$0 MOct 8, 2026
94Simplex Trading, LLC208New0.00%$0 MNov 4, 2026
95MassMutual Private Wealth & Trust, FSB203New0.00%$0 MOct 5, 2026
96Arax Advisory Partners164+163 (+16300.00%)0.00%$0 MNov 12, 2026
97California State Teachers Retirement System147-11,513 (-98.74%)0.00%$0 MNov 13, 2026
98Quarry LP122+57 (+87.69%)0.00%$0 MNov 16, 2026
99Osaic Holdings, Inc.800 (0.00%)0.00%$0 MNov 12, 2026
100EverSource Wealth Advisors, LLC28New0.00%$0 MNov 4, 2026

All 104 institutional investors, with who bought and sold →

Mutual funds holding Evommune, Inc.#

100 funds hold shares worth $84 M (about 15.0% of the company). Since their previous reports 79 added shares and 11 sold, buying $19 M net.
Mutual funds holding Evommune, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC940,119$12 M2.3%0.70%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.739,068$10 M1.8%<0.01%+132%Jun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.711,122$9 M1.7%0.06%+96%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc.554,355$7 M1.3%0.28%−9.9%Jun 30, 2026
🇺🇸 Small Cap Growth FundAmerican Century Investment Management, Inc.567,828$6 M1.4%0.11%+51%Jul 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.346,633$5 M0.84%0.04%+41%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors332,110$4 M0.80%<0.01%+37%Jun 30, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company325,000$4 M0.79%0.13%no changeJul 31, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc.258,200$3 M0.62%0.03%+53%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc.176,234$2 M0.43%0.14%−11%Jun 30, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I92,684$2 M0.22%0.17%+1.4%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.126,549$2 M0.31%<0.01%+1.3%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors119,063$2 M0.29%0.01%+169%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC138,618$2 M0.34%<0.01%+33%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC58,033$1 M0.14%<0.01%+19%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.53,877$1 M0.13%<0.01%+452%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.53,264$1 M0.13%<0.01%+19%May 31, 2026
🇺🇸 Small Cap Growth FundThe Variable Annuity Life Insurance Company38,499$1 M0.09%0.17%no changeMay 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors42,650$1 M0.10%0.04%+61%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Mid Cap ETFT. Rowe Price Associates, Inc.40,640$1 M0.10%0.02%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC20,417$0 M0.05%<0.01%+12%May 31, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc.29,866$0 M0.07%0.02%+6.4%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC17,018$0 M0.04%<0.01%−3.4%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.30,830$0 M0.07%<0.01%+34%Jul 31, 2026
🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC25,200$0 M0.06%0.03%+44%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.23,915$0 M0.06%0.04%+46%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC23,699$0 M0.06%<0.01%+40%Jun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.19,515$0 M0.05%0.02%newJun 30, 2026
🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc.18,900$0 M0.05%0.03%+80%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC15,368$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC16,861$0 M0.04%<0.01%+35%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC13,871$0 M0.03%<0.01%+32%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC11,880$0 M0.03%0.01%+184%Jun 30, 2026
🇺🇸 Column Small Cap FundTrust for Professional Managers6,194$0 M0.01%0.03%no changeMay 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.6,000$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.12,000$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.9,814$0 M0.02%<0.01%+61%Jun 30, 2026
🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC9,500$0 M0.02%0.08%+100%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation9,300$0 M0.02%<0.01%+35%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.5,125$0 M0.01%<0.01%+425%May 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC8,201$0 M0.02%0.04%+48%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC8,180$0 M0.02%<0.01%+169%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company4,321$0 M0.01%<0.01%newMay 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.3,866$0 M<0.01%<0.01%+1123%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.6,535$0 M0.02%<0.01%+22%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,464$0 M0.02%<0.01%+25%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION3,500$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.7,036$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC5,933$0 M0.01%0.04%+48%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC5,273$0 M0.01%<0.01%+23%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC5,140$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC6,073$0 M0.01%<0.01%+33%Jul 31, 2026
🇺🇸 iShares Morningstar Small-Cap Growth ETFBlackRock Fund Advisors5,847$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC5,757$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC5,133$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.4,200$0 M0.01%<0.01%+17%Jun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC4,165$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,861$0 M<0.01%<0.01%+40%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC3,500$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC3,986$0 M<0.01%<0.01%+2.7%Jul 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.3,849$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.3,140$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,876$0 M<0.01%0.02%+55%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS2,811$0 M<0.01%<0.01%+40%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC2,665$0 M<0.01%<0.01%+38%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC2,137$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 FlexShares Morningstar US Market Factor Tilt Index FundNorthern Trust Investments, Inc.2,528$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,991$0 M<0.01%<0.01%+37%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,918$0 M<0.01%<0.01%+164%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.1,911$0 M<0.01%<0.01%+65%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.2,219$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,806$0 M<0.01%<0.01%+40%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.2,056$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC1,912$0 M<0.01%<0.01%+13%Jul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC1,601$0 M<0.01%<0.01%+45%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.888$0 M<0.01%<0.01%+380%May 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC1,717$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,485$0 M<0.01%<0.01%+31%Jul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,153$0 M<0.01%0.01%+142%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,013$0 M<0.01%<0.01%+29%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,002$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,156$0 M<0.01%<0.01%+42%Jul 31, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS918$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC888$0 M<0.01%<0.01%+39%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC492$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management855$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC970$0 M<0.01%<0.01%+116%Jul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC811$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Allocation: Aggressive FundAmerican Century Strategic Asset Allocations Inc950$0 M<0.01%<0.01%+26%Jul 31, 2026
🇺🇸 iShares Morningstar Small-Cap ETFBlackRock Fund Advisors831$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC388$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC384$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC611$0 M<0.01%<0.01%−7.3%Jun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC575$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC543$0 M<0.01%<0.01%+71%Jun 30, 2026
🇺🇸 Strategic Allocation: Moderate FundAmerican Century Strategic Asset Allocations Inc630$0 M<0.01%<0.01%+1.9%Jul 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC248$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC274$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.248$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.21$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Evommune, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$164 K
3 purchases, 3 insiders
Sold, 12 months
$2.3 M
9 sales, 6 insiders
Net, 12 months
-$2.1 M
open market only
Insiders on file
14
since
$45.0 M-$1.5 M$0Nov 2025: bought $45.0 M (4 trades), sold $0 (0 trades)Nov 25Dec 2025: bought $17 K (1 trades), sold $0 (0 trades)DecMay 2026: bought $0 (0 trades), sold $740 K (2 trades)MayJun 2026: bought $0 (0 trades), sold $1.5 M (7 trades)JunJul 2026: bought $146 K (2 trades), sold $0 (0 trades)Jul
Bought (open market)Sold (open market)Hover a month for the totals
Evommune, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Luis C. PenaPresident & CEO, DirectorGrant or award+1,115$7.020$8 K631,573Form 4
filed Kyle CarverChief Financial OfficerBuy+1,000$13.26$13 K60,335Form 4
filed Arthur S. KirschDirectorBuyindirect+10,000$13.30$133 K10,000Form 4
filed Jeegar Pravinkumar PatelChief Scientific OfficerOption exercise10b5-1 plan+1,488$3.840$6 K47,891Form 4
filed Luis C. PenaPresident & CEO, DirectorSell10b5-1 plan-7,438$22.71$169 K630,458Form 4
filed Janice Suzann DrewChief of Dev. OperationsOption exercise10b5-1 plan+3,839$3.840$15 K71,633Form 4
filed Jeegar Pravinkumar PatelChief Scientific OfficerSell10b5-1 plan-1,488$22.50$33 K46,403Form 4
filed Janice Suzann DrewChief of Dev. OperationsOption exercise10b5-1 plan+16,161$2.990$48 K87,794Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Evommune, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.4 M
10.7% of shares · 2.96 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: priced at $16.00, raising $150M · IPO calendar

Stock splits: 1-for-8.52 reverse split

Fails to deliver

  • : 7,646 shares at $6.81
  • : 16 shares at $9.60
  • : 379 shares at $13.23
  • : 5 shares at $15.01
  • : 5,581 shares at $13.38

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Evommune, Inc. scorecard#

Passes 4 of the 13 checks that could be worked out: strongest in valuation (1 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median21.7×Price to sales 21.7× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-27.2%Free cash flow is -27.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • ✓Revenue grew in the newest year85.7%Revenue up 85.7% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-11.22 vs -45.29Diluted EPS -11.22 in fiscal 2025 against -45.29 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$69 MNet income -$69 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-623.6%-623.6% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-224.6%-224.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 2
    • ✓Short-term assets cover short-term liabilities8.6×Current ratio 8.57 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • ✓Altman Z-score outside the distress zone6.93Z-score 6.93 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year307.0%Diluted shares up 307.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Evommune, Inc.'s statements, beside the median of Biotechnology.

Evommune, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-623.6%-60.5%
Net margin-529.8%-68.9%
Return on equity-224.6%-61.0%
Revenue growth85.7%15.8%
Free cash flow margin-589.9%-61.5%

2of 7on the Piotroski tests of financial strength

  • Net loss of $69 million.
  • Free cash flow was negative: -$77 million.
  • The share count rose 307.0% in the year.

Evommune, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Evommune, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Revenue137.0
Research and development7464
General and administrative2013
Operating expenses9477
Operating income−81−70
Interest and finance income3.33.2
Other non-operating income (expense)123.2
Income before tax−69−68
Income tax00
Net income including minority interests−69−67
Net income attributable to shareholders−69−67
Earnings per share, basic-11.22-45.29
Earnings per share, diluted-11.22-45.29
Shares, weighted average (basic)6.11.5
Shares, weighted average (diluted)6.11.5
Balance sheet
Cash and cash equivalents4416
Short-term investments10556
Other current assets4.31.9
Current assets15374
Property, plant and equipment1.01.3
Right-of-use (leased) assets1.50.5
Long-term investments67—
Total assets22576
Accounts payable7.88.3
Current liabilities1828
Lease liabilities (non-current)1.3—
Total liabilities1929
Retained earnings−221−152
Shareholders' equity206−144
Total liabilities and equity22576
Shares outstanding321.6
Cash-flow statement
Depreciation and amortization0.60.5
Share-based compensation5.91.7
Cash from operating activities−76−58
Capital expenditure−0.2−0.1
Cash from investing activities−115−4.0
Cash from financing activities22149
Change in cash29−13
Report10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Evommune, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 5

Evommune, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Evommune, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$116 MNo. 4$50 to $250 million25equitySEC
Mar 2023$58 MNo. 3$50 to $250 million16equitySEC
Aug 2021$82 MNo. 2$50 to $250 million10equitySEC
Jun 2020$12 MNo. 1$10 to $50 million18equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Discuss Evommune, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Evommune, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $31 million.

  • Mutual funds: 100 funds hold $84 millionautomatic update · Jul 31, 2026

    100 mutual funds in 1 country hold shares of Evommune, Inc. worth $84 million, about 15.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 79 funds added shares and 11 sold; on balance they bought $19 million. Share splits are not counted as trading.

How Evommune, Inc. compares in Biotechnology

  • Market cap$282 M · higher than 50% of 726
  • Revenue$13 M · higher than 46% of 647
  • Net margin-529.8% · higher than 12% of 408
  • Revenue growth85.7% · higher than 80% of 438
  • Price / sales21.7× · lower than 30% of 339
  • Price / book1.4× · lower than 70% of 534
  • FCF yield-27.2% · higher than 36% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Evommune, Inc.🇺🇸$282 M—-529.8%+85.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Evommune, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Evommune, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Evommune, Inc.? Suggest a correction